

Correction of acidosis in chronic kidney disease (CKD)

| | | |
|--|--|--|
| Submission date 03/12/2007 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered |
| | | <input type="checkbox"/> Protocol |
| Registration date 18/01/2008 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan |
| | | <input checked="" type="checkbox"/> Results |
| Last Edited 04/07/2011 | Condition category Urological and Genital Diseases | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Muhammad Magdi Yaqoob

Contact details
Renal Unit
Royal London Hospital
Whitechapel
London
United Kingdom
E1 1BB

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
P/01/211

Study information

Scientific Title

Effects on progression of renal failure and nutritional status by correction of metabolic acidosis in patients with non-dialysis dependent chronic kidney disease (CKD)

Study objectives

Experimental data suggest that acidosis induced excessive renal ammoniogenesis and activation of the complement cascade by the alternative pathway, lead to rapid progression of renal failure which can be attenuated by bicarbonate supplementation. Moreover, metabolic acidosis accelerates protein catabolism and causes malnutrition due to an induced negative nitrogen balance in patients with end-stage renal disease (ESRD). We propose that correction of acidosis will attenuate the progression of renal failure and will improve nutritional status in patients with non-dialysis dependent chronic kidney disease.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The study is approved by the Local Research Ethics Committee from April 2002 to July 2006 (ref: P/01/211).

Study design

Randomised prospective parallel group study of patients in stage 4 and 5 CKD

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet**Health condition(s) or problem(s) studied**

Chronic kidney disease

Interventions

Sodium bicarbonate versus no treatment.

Duration of treatment: 2 years

Method of intake: oral

Frequency of treatment: daily 600 mg three times a day to be titrated up by 600 mg till serum bicarbonate level of greater than 21 mmol/l were achieved

Duration of follow up: 2 years

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Sodium bicarbonate

Primary outcome measure

The primary end points were number of patients reaching ESRD and rate of decline of estimated glomerular filtration rate (eGFR) by Cockcroft-Gault equation and creatinine clearance (Cr Cl) (24 hours urine sample).

Primary end points are measured every three months.

Secondary outcome measures

Nutritional parameters assessed by:

1. Dietary protein intake
2. Protein catabolic rate (PCR)
3. Serum albumin
4. Mid-arm muscle circumference (MAMC)

Secondary end points measured every six months.

Overall study start date

30/04/2002

Completion date

30/07/2006

Eligibility**Key inclusion criteria**

1. Age greater than 18 years old
2. CKD stage 4 and 5
3. Mild to moderate metabolic acidosis (serum bicarbonate less than 21 and greater than 16 mmol/L) on two consecutive measurements
4. Stable clinical condition

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

134

Key exclusion criteria

Patients with:

1. Malignant disease
2. Morbid obesity
3. Cognitive impairment
4. Chronic sepsis
5. Poorly controlled blood pressure (greater than 150/90 mmHg), despite use of four agents
6. Overt congestive heart failure

Date of first enrolment

30/04/2002

Date of final enrolment

30/07/2006

Locations**Countries of recruitment**

England

United Kingdom

Study participating centre**Renal Unit**

London

United Kingdom

E1 1BB

Sponsor information**Organisation**

Barts and the London NHS Trust (UK)

Sponsor details

c/o Gerry Leanord

Research and Development Directorate

Whitechapel

London

England

United Kingdom

E1 1BB

Sponsor type

Hospital/treatment centre

Website

<http://www.bartsandthelondon.org.uk/>

ROR

<https://ror.org/00b31g692>

Funder(s)

Funder type

Government

Funder Name

Barts and the London NHS Trust (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| Results article | results | 01/09/2009 | | Yes | No |